ERBB2 and colorectal cancer: Namely, one clinical study was terminated early, after the first patient (with colorectal cancer) died as a result of pulmonary toxicity, cytokine storm, and multiorgan failure arising following infusion of the HER2 neu targeted CAR T cells (81).